{
    "2018-01-01": [
        [
            {
                "time": "2018-01-01",
                "original_text": "Eli Lilly’s Cardiovascular Products Portfolio in 3Q17",
                "features": {
                    "keywords": [
                        "Cardiovascular",
                        "Products",
                        "Portfolio",
                        "3Q17"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "Eli Lilly’s Endocrine Product Portfolio in 3Q17",
                "features": {
                    "keywords": [
                        "Endocrine",
                        "Product",
                        "Portfolio",
                        "3Q17"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "Eli Lilly & Co. breached its 50 day moving average in a Bearish Manner : LLY-US : January 1, 2018",
                "features": {
                    "keywords": [
                        "breached",
                        "50 day moving average",
                        "Bearish",
                        "LLY-US"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "Eli Lilly’s New Products Portfolio in 3Q17",
                "features": {
                    "keywords": [
                        "New",
                        "Products",
                        "Portfolio",
                        "3Q17"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}